Nxera Pharma has entered into an exclusive global licensing agreement with AbbVie for NXE0033744, an investigational oral EP4 ...
Transgene and Bispebjerg and Frederiksberg Hospital, University of Copenhagen, have announced that the first patient has been ...
PharmaTimes looks PM Andy Burnham in the eye and asks, what are you going to do for us? We also stare down the ubiquitous AI ...
Teva Pharmaceutical Industries and Samsung Bioepis have announced a new licensing and commercialisation agreement covering ...
A new £30 million venture philanthropy fund is being launched to accelerate the development of treatments, diagnostics and technologies aimed at finding a cure for myeloma, an incurable blood cancer ...
Octane Biotech and Currus Biologics have automated the manufacturing process for CUR‑001 on Octane’s Cocoon platform, ...
Santersus is advancing NUC‑CAP, a multicentre, randomised pivotal study of NucleoCapture, its investigational extracorporeal ...
The ExoCordOA consortium has launched a five‑year, €13 million Horizon Europe project to advance extracellular ...
Panthera has opened its expanded Glasgow Clinical Research Centre at the Health Innovation Hub, increasing capacity for ...
Hansa Biopharma has announced positive data from the European Post‑Authorization Efficacy and Safety study of Idefirix, ...
Hutchmed has confirmed that regulatory filings for Orpathys plus Tagrisso have been accepted for review in Europe and Japan.
Hutchmed has announced positive phase 3 results from the SANOVO trial evaluating ORPATHYS plus TAGRISSO in treatment‑naïve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results